Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) went up by 0.43% during the previous trading session, and it is maintaining the win ahead of Monday’s trading session. The share price of the Biotechnology giant went up by $25.78 to trade ended Monday trading at $25.67. This is up from the $25.67 price recorded on Thursday’s trading session. Thanks to this latest performance, DRNA is closer to the higher price 52-week target of $45.00 and further from the lowest price target of $25.00. Its performance from the start of the year has also been positive, with DRNA up by 17.02% year-to-date.
Dicerna Pharmaceuticals Inc. (DRNA) started the day trading at $26.13 and recorded an intraday high of $26.34. It also recorded an intraday low of $25.39 during Monday’s trading session. Dicerna Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -43.66% of the average daily trading volume on Monday. The stock’s trading volume on Monday was 470192, which is less than -43.66 of the total average daily trading volume of 675.46K.
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) 2020 Performance Impressive
The increase in DRNA’s stock price on Monday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of DRNA currently stands at $27.68, which is higher than the current trading price of the stock by 6.86%. However, DRNA’s current trading price is -119.4% lower than the 52-week low price of $11.75. In terms of trading volume, Dicerna Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 470192 shares of Dicerna Pharmaceuticals Inc. were traded on the stock exchange on Monday, which is less than -43.66% of the 675.46K average trading volume of the stock.
The performance of the stock has been positive over the past year. DRNA’s performance over the past one year has seen it surge by 74.90%, while the stock has gone up by 21.29% in the last six months. The quarterly performance of DRNA currently stands at 44.02%, and it is up by 31.80% in the last month. The only positive figure was from the weekly performance, which currently reads 2.26%. At the time of writing DRNA’s report, the company has a total market cap of $1.98B, making it one of the largest publicly-traded companies in the world.Dicerna Pharmaceuticals Inc. also has over 187 employees all over the world.
DRNA Insider Activities
For Dicerna Pharmaceuticals Inc., insiders hold 86.90% of all company shares. The insider transactions over the past six months are down by 0.00%. During that period, insiders bought 193,019 shares in 19 transactions. In that same period, insiders sold 193,019 of their shares in 17 transactions. After these transactions, insiders at Dicerna Pharmaceuticals Inc. now hold 5.54M shares, which is over 83.07% of the total company stocks. Institutional investors currently hold a large chunk of the DRNA shares, as they control 7.49% of the company’s total stock.
DRNA Fundamental Analysis
For Dicerna Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at -1.69. In the coming year, analysts expect the EPS to be -0.53. The stock’s EPS growth this year is -10.20%, 10.10% in the previous five years. In terms of revenue, Dicerna Pharmaceuticals Inc.’s quarterly sales (YOY) is growing at 0.10, which is lower than the average annual revenue of 10.10% over the past half a decade.
The Return on Investment (ROI) on Dicerna Pharmaceuticals Inc.’s stock currently stands at -84.20%.
DRNA Analysts Prediction
Another analyst that has a Buy rating for DRNA is H.C. Wainwright, which set a price target of between $22 and $30.
Citigroup and Citigroup also believe that Dicerna Pharmaceuticals Inc.’s stock is outperforming at the moment. DRNA received a positive rating from B. Riley FBR, which set a price target of $13.50-$21 for the stock.
DRNA Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of DRNA currently stands at 10.81%, while the SMA50 is 15.72%. The biggest one is the SMA200, which is currently reading 27.83% ahead of Monday’s trading session. The Relative Strength Index of this stock is 60.28.
